ERBB2 and triple-negative breast carcinoma: Furthermore, neoadjuvant treatments aid in the prognostication of the tumors and individualization of the adjuvant treatments, as seen in the low rates of recurrence in patients with HER-2-positive breast cancer and triple-negative breast cancer who had pCR with neoadjuvant treatment [28,29].